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Abstract
Familial Hemophagocytic lymphohistiocytosis (FHL) is a rare immune deficiency with defective cytotoxic function. The age
at onset is usually young and the natural course is rapidly fatal if untreated. A later onset of the disease has been
sporadically reported even in adolescents and adults. We report the results of our retrospective data collection of all cases
diagnosed with FHL at an age of 18 years or older and enrolled in the Italian Registry of HLH. All cases were diagnosed with
FHL based on evidence of genetic defect in one FHL-related gene. A total of 11 patients were diagnosed with FHL. They
were 9 males and 2 females, from 10 unrelated families; their age ranged between 18 and 43 years (median, 23 years).
Family history was unremarkable in eight families at the time of the diagnosis. Their genetic diagnoses are: FHL2 (n = 6),
FHL3 (n = 2), FHL5 (n = 1), XLP1 (n = 2). Clinical, molecular and functional data are described. These data confirm that FHL
may present beyond the pediatric age and up to the fifth decade. FHL2 due to perforin defect is the most frequently
reported subtype. Adult specialists should consider FHL in the differential diagnosis of patients with cytopenia and liver or
central nervous system disorders, especially when a lymphoproliferative disease is suspected but eventually not confirmed.
FHL may turn to be fatal within a short time course even in adults. This risk, together with the continuous improvement in
the transplant technique, especially in the area of transplant from matched unrelated donor, resulting in reduced treatment
related mortality, might suggest a wider use of SCT in this population. Current diagnostic approach allows prompt
identification of patients by flow-cytometry screening, then confirmed by the genetic study, and treatment with chemo-
immunotherapy followed by stem cell transplantation.
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Introduction
Familial Hemophagocytic lymphohistiocytosis (FHL, OMIM
267700) is a genetically heterogeneous disorder characterized by a
hyper-inflammatory syndrome with fever, hepatosplenomegaly,
cytopenia and sometimes central nervous system involvement.
Bone marrow aspiration is usually performed early during the
diagnostic work-up, enabling the identification of haemophagocy-
tosis by activated macrophages [1]. In most cases the natural
course of FHL is rapidly fatal within a few weeks, unless
appropriate treatment, including corticosteroids, cyclosporine,
etoposide, anti-thymocyteglobulin, can obtain transient disease
control. So far, only patients who underwent hematopoietic stem
cell transplantation have been cured [1–5].
Diagnosing FHL has been challenging for clinicians for many
years. Initially, the key points for the diagnosis of HLH have been
the diagnostic criteria, established by the Histiocyte Society,
collecting both clinical and biochemical features, all rapidly
available to the attending physician. Recently, the diagnostic
criteria have been updated to introduce sCD25 level but, even
more important, hyperferritenemia and defective natural killer
activity [6]. Better understanding of the pathogenic mechanisms of
FHL provided the rationale for developing novel, sensitive and
specific diagnostic tools based on flow-cytometry analysis of
peripheral blood cells. In particular, evidence of defective
expression of intra-cytoplasmic perforin, as well as defective
degranulation upon stimulation of the cytotoxic effector cells,
provided very potent tools for initial screening of patients with
suspected FHL [7,8].
FHL is associated with an overactive adaptive immune system,
probably resulting from the failure of activated CTLs and NK cells
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to clear APCs and therefore to terminate an immune response [9–
11]. The uncontrolled expansion and activation of polyclonal
CD8+ T cells may lead to macrophage activation, with infiltration
of tissues and organs, together with excessive release of inflam-
matory cytokines which also causes tissue damaging.
Since 1999, several genes have been associated with FHL: PRF1
(OMIM *170280), UNC13-D (OMIM *608897), STXBP-2
(OMIM *601717) and Syntaxin-11 (OMIM *605014), all encoding
proteins which play a key role in lymphocyte cytotoxicity [12–16].
Additional congenital immune deficiencies may expose the patient
to develop a clinical picture overlapping FHL. Patients with
Chediak-Higashi syndrome have biallelic mutations of the gene
encoding the cytoplasmic protein lysosomal trafficking regulator
(LYST;OMIM*606897) and have granulated cells with giant
intracytoplasmic lysosomal structures. Griscelli syndrome type 2
(GS2) is characterized by hypopigmentation (owing to defective
release of melanosome contents from melanocyte dendrites) and
defective CTL and NK cell cytotoxic activity. Biallelic mutations
in the gene encoding RAB27a (OMIM*603868) are responsible
for GS2 [11,17]. Finally, several primary immunodeficiency
syndromes, including X-linked lymphoproliferative disease (XLP)
type I due to hemizygous mutation of SH2D1Agene, OMIM
*300490), and type II due to mutation of BIRC4/XIAP gene
(OMIM *300079) are associated with a high risk of developing
HLH [18,19].
The age at diagnosis of FHL is often very young. Since the
original report of two affected siblings aged nine weeks by James
Farquhar in 1952 [20], FHL has widely been considered as a
disease characteristic of the first two years of age. This may
mislead the clinician into conclude that a patient with a clinical
constellation resembling HLH is simply considered to be ‘‘too old’’
for this diagnosis. Over the years, sporadic reports of older
children and adolescents have raised the issue of a possible
‘‘threshold’’ age for diagnosing FHL [21,22].
Here we report a series of patients with FHL due to a
documented genetic defect who developed the disease during
adulthood.
Results
A total of eleven patients were diagnosed with FHL based on
the finding of mutations in one FHL-related gene. They included 9
males and 2 females, from ten unrelated families; their age ranged
between 18 years and 43 years (median, 23 years). Their main
presenting features are summarized in Table 1. Nine families were
of Italian origin, and one was from Colombia. Family history was
unremarkable in eight families at the time of the diagnosis.
Consanguinity was reported in two families.
Patient 198 developed the disease at 18 years with a typical
picture. Specific therapy was rapidly followed by disease control,
but unfortunately the child died of complication within a few
months. Patient 199 had been diagnosed with fulminant mono-
nucleosis, and the diagnosis of HLH was made when he was at a
terminal stage. XLP1 was then diagnosed retrospectively.
Patient 232 and 233 belong to the same family, and preliminary
data had been reported soon after the diagnosis [22]. Patients 232
developed, at 22 years, isolated, asymptomatic hypertransamina-
semia, followed, a few months later, by left arm weakness lasting
one month; then, at 27 years, again fever, lymphadenopathy,
pancytopenia and neurologic symptoms (hemiplegia and somno-
lence). Multifocal brain demyelination lead to a diagnosis of
neurosarcoidosis, treated with high doses i.v. glucocorticoid with
good clinical response. Oral prednisone was progressively tapered
but a minimal dose of 40 mg daily was required to control fever
and asthenia, while pancytopenia persisted, with recurrent
respiratory and urinary infections. We first saw him two years
later with fever, dyspnea, herpes simplex lesions in nasal and
perioral skin, marked hepatosplenomegaly, and severe Cushingoid
features; pancytopenia, hypofibrinogenemia, hypertriglyceridemia,
high levels of transaminases, cholestatic indexes, and ferritin, with
hemophagocytosis were observed. He refused allergenicstem cell
transplantation (SCT) and remained clinically stable for 10 years
until eventually developing full-blown FHL with severe CNS
involvement, which turned to be fatal. Family history at the time of
the diagnosis had revealed that his sister (patient 233), had been
diagnosed with non-Hodgkin lymphoma and treated with
chemotherapy followed by autologous SCT. Diagnostic work-up
confirmed FHL2 redirecting interpretation of the initial episode
(fever, weight loss, weakness, hepatosplenomegaly, pancytopenia,
hypertriglyceridemia, hypofibrinogenemia, hyperferritinemia, with
polyclonal T-cell lymphoproliferation). She remained asymptom-
atic for over 10 years but eventually developed full-blown FHL at
the age of 37 years. At the time of writing she is being treated with
allogeneic SCT at another centre.
Patient 276 developed full-blown HLH at 22 years but refused
treatment with a rapidly fatal course.
The medical history of patient 525 revealed tonsillectomy at the
age of 5 years and two other similar ’infectious mononucleosis like’
bouts at the age of 7 and 22 years, which resolved spontaneously.
At the age of 23 years he had another similar episode, which
gradually recovered within 10 days. However, a month later he
was readmitted with a similar picture, ascites and pleural effusion.
HLH was suspected and confirmed by the functional and genetic
study. Following chemo-immunotherapy according to HLH-2004
protocol, he achieved disease control and was then successfully
treated with allogeneic SCT.
Patient 557 was diagnosed with full-blown FHL occurring as his
first relevant health problem at the age of 39 year. FHL2 was
diagnosed based on absent perforin expression and biallelic
mutations, compatible with parental consanguinity. Unfortunately
he died during initial therapy due to progressive disease. Soon
thereafter, during the genetic study of the family, his 17-month-old
daughter was found to be compound heterozygous due to a
maternal nonsense PRF mutation and developed full-blown FHL.
One elder sister of patient 557 had died at the age of 16 year of
progressive encephalopathy with cytopenia, and genetic confir-
mation of her diagnosis of FHL awaits availability of diagnostic
tissue.
Patients 577 and 667 developed full-blown, rapidly progressive
FHL as their first major health problem at 28 and 43 years,
respectively.
Patient 705 developed, at the age of 19 years, a typical HLH,
diagnosed as so in one of our pediatric centers. Patient 715 was
admitted to an Infectious disease academic unit where HLH was
suspected and then confirmed by the centralized diagnosis.
Discussion
Most of the available information on the clinical spectrum and
natural course of FHL derives from reports of children diagnosed
by a few referral centres in Europe, North America or Japan [1–
2]. This lead to the common belief that FHL is restricted to
children or infants, and does not pertain to adult patients.
Although the vast majority of patients did indeed develop the
disease during the first few years of life, the concept that later onset
of HLH is possible has been repeatedly brought to the attention of
adult haematologists [21,22,26]. Nevertheless, adult patients are at
most considered as potentially affected by the so-called ‘‘second-
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ary’’ form of HLH, also defined in the past as ‘‘virus (or infection)
associated hemophagocytic syndrome’’ (VAHS or IAHS) [27]
rather than by genetic FHL. This may have several implications,
the most important being reluctance to apply a complete, standard
therapy for FHL, which at present consists of chemo-immuno-
therapy with dexamethasone and etoposide, then followed by
cyclosporine, as defined by the HLH94 study [2,28]; its primary
aim is to achieve disease control and then forward the patient to
allogeneic SCT, the only currently available treatment with
potential for cure [2,4–5]. Genotype-phenotype studies of FHL
have established a close correlation between biallelic disruptive
mutations and early age at the onset of FHL [29,30]. In the
presence of hypomorphic genetic defects, residual protein allows
some level of residual NK- and T-cell function, which may
become sufficient to cope with infectious agents, the usual triggers
of FHL, for many years. We report on six patients with FHL2 due
to compound heterozygosity, in whom at least one allele carried a
missense mutation. In four of these six, it was the PRF1 A91V
single nucleotide change. Although its pathogenic role has been
widely debated, due to its 2–5% frequency at the heterozygous
state in control population, its pathogenic role on perforin protein
has been clearly documented [23,29].
In a recent similar report, Zhang et al. described 10 adult
patients with FHL due to biallelic mutations; of them 7 had FHL2,
and A91V was found in 5 of the 14 mutated alleles [31].
Based on the pediatric experience, diagnostic criteria have been
developed. This set of eight clinical and laboratory items, which
proved to be sufficiently sensitive and specific, might be updated
using a more practical clinical approach. Patients with fever,
splenomegaly, thrombocytopenia and high levels of ferritin, in
whom bone marrow aspirate does not document leukemia, should
be rapidly screened by flow-cytometry for the expression of
intracytoplasmic perforin and the ability to degranulate– as
measured by surface expression of CD107a upon appropriate
stimulation – of the peripheral blood lymphocytes [8]. This
procedure, widely accessible to haematology or immunology
laboratories, can predict the presence of mutations in the PRF1 or
in the UNC13D, STX11, STXBP2 genes, respectively [32]. This
approach may be expected to cover most of the cases of FHL, thus
providing a robust support to the diagnosis and justification for
high-risk treatment in life-threatening conditions, including
indication to SCT.
The question about indication to SCT for patients with milder
clinical picture or even in a presymptomatic phase remains open.
Increasing body of evidence suggests that full-blown FHL may
turn to be fatal within a short time following the diagnosis, even in
adults with hypomorphic mutations. This risk, together with the
continuous improvement in the transplant technique, especially in
the area of transplant from matched unrelated donor, resulting in
reduced treatment related mortality, might suggest a wider use of
SCT in this population.
Methods
Setting
Starting from 1984 a Registry for HLH was established [1]. The
pediatric community in the country was offered the opportunity to
centralize patient information and biologic samples, in order to
confirm the clinical diagnosis and to perform centralized
immunological and genetic studies, since the time these last
became available.
Hemophagocytic Lymphohistiocytosis was defined by the
diagnostic criteria established by the Histiocyte Society [6].
Immunological Analyses
Peripheral blood mononuclear cells (PBMC) from FHL patients
and healthy donors were isolated by Ficoll gradient centrifugation.
NK cells were also purified using the RosetteSep method
(StemCell Technologies, Vancouver, British Columbia, Canada)
following manufacturer’s instructions. NK cells were cultured on
irradiated feeder cells in the presence of 2 mg/mL phytohemag-
glutinin (Sigma-Aldrich, Irvine, UK) and 100 U/mL rIL-2
(Proleukin, Chiron Corp., Emeryville, USA) to obtain high
numbers of polyclonal activated NK cell populations.
Perforin expression on NK cells (CD32CD56+ cells of PBL or
purified activated NK populations) was detected by intracellular
staining (after fixation and permeabilization) with DG9 mAb and
cytofluorimetric analysis, as previously reported [23].
To analyse the cytolytic activity in 4-h 51Cr-release assays,
PBMC were tested against K562, while activated NK cells were
tested against the HLA-class I- B-EBV cell line 721.221,
demonstrated to be suitable effector/target combinations to reveal
cytolytic defect of FHL patients [8]. E:T ratios ranging from 100:1
to 1:1 were used for PBMC as effector cells, while from 8:1 to 0.5:1
for activated NK. Lytic units (LU) at 30% lysis were calculated.
Resting and activated NK cells were also tested in degranulation
assay quantifying cell surface CD107a expression upon co-culture
with K562, as previously described [8]. Briefly, anti-CD107a-PE
mAb was added during the co-culture for 3 hours at 37uC in 5%
CO2. Thereafter, the cells were stained with anti-CD56-APC and
anti-CD3-PerCP mAb and analysed by flow cytometry (FACS-
Calibur, Becton Dickinson). All reagents were from BD Biosci-
ences (Oxford, UK). Surface expression of CD107a was assessed in
the CD3-CD56+ cells. Results were evaluated as DCD107a (i.e. %
CD107a+ cells of stimulated - % CD107a+ cells of unstimulated
sample) and defined defective when lower than the 10th percentile
of healthy controls.
Expression of Munc13-4 and Munc18-2 proteins was analyzed
by western blot using cell extracts and specific polyclonal
antibodies, as previously described [24,25].
Mutation Analysis
Genomic DNA was isolated from peripheral blood samples
using BioRobotH EZ1 Workstation (Qiagen, Jesi Italy) or Qiaamp
DNA Mini Kit (Qiagen, Jesi Italy), then amplified and directly
sequenced, in both directions, with the BigDyeH Terminator Cycle
SequencingReady Reaction Kit (Applied Biosystems, Foster City,
CA, USA). Amplification reactions were performed with 60 ng of
DNA, 10 ng of each primer, 200 mM dNTPs, 1x PCR reaction
buffer, and 2.5 U Taq polymerase in a final volume of 25ml.
Sequences obtained using an ABI PrismH 3130XL Sequence
DetectionSystem (Applied Biosystems) were analysed and com-
pared with the reported gene structure using the dedicated
software SeqScapeH (Applied Biosystems). All mutations were
confirmed in the parents.
PRF1, UNC13D, STXBP2 and SH2D1A genes have been
analyzed. All patients underwent direct sequencing of PCR
products spanning the coding exons and exon–intron boundaries
of the four selected genes. The sequences obtained were compared
with the reported gene structures (PRF1 gene number: 190339,
NCBI; UNC13D gene number: 201294, NCBI; STXBP2 gene
number: 6813, NCBI; SH2D1A gene number: 4068, NCBI).
Data were collected and stored in a specific Microsoft Access
data-base.
Ethics Statement
Written informed consent for the data collection including
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